Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: tktrimbath who wrote (333)	5/9/2001 8:23:02 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

CellExSys... I hold shares of Axys which has done this sort of thing-- PPGx, DPII. "Axys is building shareholder value through affiliated businesses". Hasn't seemed to help AXPH shareprice so far. I sure hope Tgen fares well with this sort of thing. I guess you are supposed to look at spinoffs as seeds planted, rather than an ever decreasing slice of the original pie. It would be great if the thread perked up a bit. I can start things off by starting to go through the names: Targeted Genetics Establishes Medical and Scientific Advisory Board for CellExSys biz.yahoo.com Brenner is Professor of Medicine and of Pediatrics and Director, Center for Cell and Gene Therapy at Baylor College of Medicine bcm.tmc.edu Baylor pops up sometimes when I get into my Valentis googlin' around--Valentis=Megabios+GeneMedicine <GeneSwitch<Baylor College of Medicine< Shuffle...shuffle, deal!